Omnicell's (OMCL) Buy Rating Reiterated at Benchmark

Omnicell (NASDAQ:OMCL - Get Free Report)'s stock had its "buy" rating restated by Benchmark in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $38.00 price objective on the stock. Benchmark's target price indicates a potential upside of 41.74% from the stock's previous close.

A number of other analysts have also recently weighed in on the company. Barclays began coverage on Omnicell in a research report on Wednesday, January 3rd. They set an "underweight" rating and a $33.00 price objective for the company. Wells Fargo & Company cut their target price on Omnicell from $28.00 to $26.00 and set an "equal weight" rating for the company in a research note on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Omnicell presently has an average rating of "Hold" and a consensus price target of $42.20.

Omnicell Stock Down 2.2 %

Omnicell stock traded down $0.59 during trading on Tuesday, reaching $26.81. The stock had a trading volume of 482,757 shares, compared to its average volume of 536,661. Omnicell has a 52-week low of $25.69 and a 52-week high of $77.14. The business has a 50 day moving average price of $27.61 and a 200 day moving average price of $31.93. The company has a quick ratio of 2.22, a current ratio of 2.52 and a debt-to-equity ratio of 0.48. The stock has a market cap of $1.23 billion, a PE ratio of -59.58 and a beta of 0.76.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, February 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.22. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. The firm had revenue of $258.85 million during the quarter, compared to the consensus estimate of $256.00 million. On average, analysts predict that Omnicell will post 0.09 EPS for the current year.

Hedge Funds Weigh In On Omnicell

Several hedge funds and other institutional investors have recently modified their holdings of the company. Arkadios Wealth Advisors boosted its stake in shares of Omnicell by 30.6% in the first quarter. Arkadios Wealth Advisors now owns 30,010 shares of the company's stock valued at $877,000 after purchasing an additional 7,025 shares during the period. Principal Financial Group Inc. increased its holdings in Omnicell by 3.9% during the 1st quarter. Principal Financial Group Inc. now owns 264,083 shares of the company's stock worth $7,719,000 after purchasing an additional 9,944 shares during the last quarter. Benjamin Edwards Inc. raised its position in shares of Omnicell by 36.4% in the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company's stock valued at $95,000 after purchasing an additional 868 shares in the last quarter. Horrell Capital Management Inc. grew its position in shares of Omnicell by 82.0% during the first quarter. Horrell Capital Management Inc. now owns 91,000 shares of the company's stock worth $2,660,000 after buying an additional 41,000 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Omnicell by 2.2% in the first quarter. Assenagon Asset Management S.A. now owns 371,835 shares of the company's stock worth $10,869,000 after buying an additional 8,096 shares during the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.